Because GRPR occurs and stimulates cell proliferation in uterine cervix cancer (7–9), radiopharmaceutical peptide–receptor cohesion might have a therapeutic value by bringing a cell-killing radionuclide directly to cancer cells. The gene discussed is GRPR; the disease is cancer.